miRNAs associated with prostate cancer risk and progression

Luu, Hung N.; Lin, Hui‐Yi; Sørensen, Karina Dalsgaard; Ogunwobi, Olorunseun O.; Kumar, Nagi B.; Chornokur, Ganna; Phelan, Catherine M.; Jones, David N. M.; Kidd, LaCreis R.; Batra, Jyotsna; Yamoah, Kosj; Berglund, Anders; Rounbehler, Robert J.; Yang, Mihi; Lee, Sang Haak; Kang, Nahyeon; Kim, Seung Joon; Park, Jong Y.; Pietro, Giuliano Di

doi:10.1186/s12894-017-0206-6

Cited by 89 publications

(98 citation statements)

References 135 publications

(233 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus to date, several miRNA profiling studies have detected differential expression patterns between PCa and BPH (summarized in). Many of them were identified by high‐throughput technologies and subsequently validated by standard PCR‐based methods; however, limited overlap has been observed among these findings.…”

Section: Discussionmentioning

confidence: 99%

Candidate diagnostic miRNAs that can detect cancer in prostate biopsy

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Candidate diagnostic miRNAs that can detect cancer in prostate biopsy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…CAPRA-S score 15 was calculated as a sum of the following: PSA at RP [6,10] = +1, (10,20] = +2, >20 = +3; prostatectomy Gleason Score 3 + 4 = +1, 4 + 3 = +2, ≥8 = +3; positive for surgical margin (SM) = +2; positive for seminal vesicle invasion = +2; positive for extracapsular extension = +1; positive for lymph node invasion = +1. CAPRA-S risk groups were then defined as [0,2] = low risk; [3,5] = intermediate risk; [6,12] = high risk.…”

Section: Patient Samples and Mirna Profilingmentioning

confidence: 99%

“…Furthermore, dysregulation of miRNAs is a hallmark of PC and has been demonstrated in both tumor tissue samples and in bodily fluids (e.g., serum, plasma and urine) . As each miRNA has the potential to regulate hundreds of target genes, even a slight dysregulation of miRNAs, brought on by, for example, chromosomal alterations or epigenetic changes, can cascade to a plethora of other cellular processes …”

Section: Introductionmentioning

confidence: 99%

“…[8][9][10][11] As each miRNA has the potential to regulate hundreds of target genes, even a slight dysregulation of miRNAs, brought on by, for example, chromosomal alterations or epigenetic changes, can cascade to a plethora of other cellular processes. 12 In the present study, we investigated whether miRNA levels in cell-free urine samples from PC patients may be used in combination with the serum PSA test to improve prediction of BCR risk after RP. Specifically, we trained, tested and successfully validated a novel logistic regression model (pCaP) that was a significant independent predictor of postoperative BCR beyond routine clinicopathological parameters in three different cohorts including 215, 199 and 205 PR patients, respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A five‐microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell‐free urine

Fredsøe

Rasmussen²,

Mouritzen³

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Improved biomarkers for prostate cancer (PC) risk stratification are urgently needed. Here, we aimed to develop a novel multimarker model for prediction of biochemical recurrence (BCR) after curatively intended radical prostatectomy (RP), based on minimally invasive sampling of blood and urine. We initially measured the levels of 45 selected miRNAs by RT‐qPCR in exosome enriched cell‐free urine samples collected prior to RP from 215 PC patients (Cohort 1, training). We trained a novel logistic regression model (pCaP), comprising five urine miRNAs (miR‐151a‐5p, miR‐204‐5p, miR‐222‐3p, miR‐23b‐3p and miR‐331‐3p) and serum prostate‐specific antigen (PSA), which significantly predicted time to BCR in Cohort 1 (univariate Cox regression analysis: HR = 3.12, p < 0.001). Next, using the same exact numeric cutoff for dichotomization as trained in Cohort 1, we tested and successfully validated the prognostic potential of pCaP in two additional cohorts, including 199 (Cohort 2, HR = 2.24, p = 0.002) and 205 (Cohort 3, HR = 2.15, p = 0.004) RP patients, respectively. pCaP remained a significant predictor of BCR, also after adjustment for pathological T‐stage, surgical margin status and Gleason grade group (p < 0.05 in multivariate Cox regression analysis: HR = 2.72, 1.94 and 1.83 for Cohorts 1, 2 and 3, respectively). Additionally, pCaP scores correlated positively with the established clinical risk stratification nomogram CAPRA in all three PC cohorts (Pearson's rho: 0.45, 0.39 and 0.44). Together, our results suggest that the minimally invasive pCaP model could potentially be used in the future to improve PC risk stratification and to guide more personalized treatment decisions. Further clinical validation studies are warranted.

show abstract

“…Recent expression profiling studies in PCa suggest that miR may serve as potential biomarkers for PCa risk and disease progression (26)(27)(28)(29)(30). Growing evidence has indicated that mutation or polymorphisms in miR genes could affect target-binding activity, expression or processes of mature miR, consequently affecting the expression of their target genes (15,16).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of a 3-base pair indel polymorphism within pre-microRNA-3131 in patients with prostate cancer using mismatch polymerase chain reaction-restriction fragment length polymorphism

Hashemi

Bahari

Sattarifard

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The present study aimed to examine the impact of a 3-bp indel (rs57408770) polymorphism within the pre-microRNA (miR)-3131 polymorphism on prostate cancer (PCa) risk in a sample of an Iranian population. In total, 340 subjects, including 177 patients with PCa and 170 patients with benign prostatic hyperplasia, were enrolled in the present case-control study. A mismatch polymerase chain reaction-restriction fragment length polymorphism method was designed for genotyping the 3-bp indel (rs57408770) polymorphism. The present findings demonstrated that the indel variant significantly increased the risk of PCa in codominant [odds ratio (OR)=2.23, 95% confidence interval (CI)=1.13-4.37; P=0.021, insertion (ins)/ins vs. deletion (del)/del] and recessive (OR=2.33, 95% CI=1.25-4.36; P=0.009, ins/ins vs. del/del + del/ins). In conclusion, to the best of our knowledge, the present findings for the first time proposed that a 3-bp indel variant of miR-3131 may be a risk factor for susceptibility to PCa in a sample of an Iranian population. Further studies with different ethnicities and larger sample sizes are required to validate the present findings. IntroductionProstate cancer (PCa), the second most common malignancy in men, is the fifth leading cause of cancer-related mortality among men globally (1). The incidence rate of PCa in Iran is lower than that in the rest of the world (2-4). Despite the high prevalence of PCa, little is known about the mechanisms underlying the development and progression of PCa. It has been proposed that genomic and environmental factors contribute to the development and progression of PCa (5-8). Twin studies have indicated that 42% of the variation in PCa risk may be attributed to genetics (9). Single nucleotide polymorphisms (SNPs), the most common type of genetic variation in the human genome, have been demonstrated to be associated with the risk of developing PCa (10-12).MicroRNA (miR) are small, non-coding, endogenous, single-stranded RNA molecules that are ~22 nucleotides in length (13,14). They regulate gene expression by directing sequence-specific degradation or inhibiting translation of target mRNA (13,14). Mounting evidence has suggested that mutation or SNPs in miR genes may affect target-binding activity, expression, or processes of mature miR, thus affecting the expression of their target genes (15,16). Polymorphisms in mature and/or pre-miR sequences may affect miR biogenesis and be associated with the development of various types of cancer (17-21). Small insertions and deletion (indels) polymorphisms are one of the most common genetic alterations in the human genome that influence human traits and diseases (22,23). There is limited information regarding the association between pre-miR-3131 polymorphisms and cancer risk. Recently, Wang et al (20) investigated the impact of a 3-bp indel polymorphism (rs57408770) in pre-miR-3131 on hepatocellular carcinoma (HCC) and observed that the insertion (ins) allele significantly increased the risk of HCC in a Chinese population. ...

show abstract

miRNAs associated with prostate cancer risk and progression

Cited by 89 publications

References 135 publications

Candidate diagnostic miRNAs that can detect cancer in prostate biopsy

Candidate diagnostic miRNAs that can detect cancer in prostate biopsy

A five‐microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell‐free urine

Evaluation of a 3-base pair indel polymorphism within pre-microRNA-3131 in patients with prostate cancer using mismatch polymerase chain reaction-restriction fragment length polymorphism

Contact Info

Product

Resources

About